Literature DB >> 22376267

The value proposition of molecular medicine.

Scott A Waldman1, Andre Terzic.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22376267      PMCID： PMC5404828          DOI： 10.1111/j.1752-8062.2011.00386.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  24 in total

1.  Patient-centric clinical pharmacology advances the path to personalized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

2.  The roadmap to personalized medicine.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

3.  Translational medicine: path to personalized and public health.

Authors:  Andre Terzic; Scott A Waldman
Journal:  Biomark Med       Date:  2010-12       Impact factor: 2.851

4.  Induced pluripotent stem cells: an emerging theranostics platform.

Authors:  T J Nelson; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2011-05       Impact factor: 6.875

5.  Optimizing cancer care: is the future bright?

Authors:  P Zahedi; R De Souza; M Piquette-Miller
Journal:  Clin Pharmacol Ther       Date:  2011-09       Impact factor: 6.875

6.  Comparative effectiveness: the fourth hurdle in drug development and a role for clinical pharmacology.

Authors:  P K Honig
Journal:  Clin Pharmacol Ther       Date:  2011-02       Impact factor: 6.875

Review 7.  Therapeutic additions and possible deletions in oncology in 2011.

Authors:  S A Holstein; R J Hohl
Journal:  Clin Pharmacol Ther       Date:  2012-01       Impact factor: 6.875

8.  Molecular therapy drives patient-centric health care paradigms.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2010-08       Impact factor: 4.689

9.  BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells.

Authors:  Elisa Sala; Luca Mologni; Silvia Truffa; Carlo Gaetano; Gideon E Bollag; Carlo Gambacorti-Passerini
Journal:  Mol Cancer Res       Date:  2008-05-05       Impact factor: 5.852

10.  Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.

Authors:  A O'Donnell; I Judson; M Dowsett; F Raynaud; D Dearnaley; M Mason; S Harland; A Robbins; G Halbert; B Nutley; M Jarman
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640
View more
  1 in total

Review 1.  Mass Customized Outlook for Regenerative Heart Failure Care.

Authors:  Satsuki Yamada; Jozef Bartunek; Atta Behfar; Andre Terzic
Journal:  Int J Mol Sci       Date:  2021-10-22       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.